OTLK Outlook Therapeutics

Outlook Therapeutics® to Present at the BTIG Ophthalmology Day

Outlook Therapeutics® to Present at the BTIG Ophthalmology Day

ISELIN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that of Outlook Therapeutics, will present in a fireside chat at the virtual BTIG Ophthalmology Day on November 29, 2022 at 12:30 PM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. For more information, please visit .

CONTACTS:

Media Inquiries:

Anna Army

Account Supervisor

LaVoie Health Science

T: 617-351-0246

Investor Inquiries:

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 833.475.8247 



EN
22/11/2022

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break ...

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event Live webcast on Wednesday, June 25th at 12:00 PM ET ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a on Wednesday, June 25, 2025 at 12:00 PM ET. As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP – Head of Europe...

June 18, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevac...

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizum...

June 10, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevaci...

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (b...

June 2, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offeri...

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares of its common stock, together with accompanying warrants to purchase 18,571,428 shares of its common stock. The combined public offering price of common stock and accompanying warrant is $1.40. The common stock is being sold ...

May 23, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics® Announces Proposed Public Offering of Common Sto...

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be complet...

May 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch